Cargando…

Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis

BACKGROUND: With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Zepei, Zhang, Jinwei, Tan, Weilong, Wang, Chunhui, Chen, Qiong, Shen, Chao, Fan, Haozhi, Zhang, Yun, Huang, Peng, Yue, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158331/ https://www.ncbi.nlm.nih.gov/pubmed/35665327 http://dx.doi.org/10.3389/fmed.2022.802686

Ejemplares similares

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
por: Czarnecka, Paulina, et al.
Publicado: (2022)

Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry
por: Franco, Antonio, et al.
Publicado: (2023)

Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients
por: Axelrod, David A., et al.
Publicado: (2020)

Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
por: Eckman, Mark H., et al.
Publicado: (2021)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting
por: Concepcion, Beatrice P., et al.
Publicado: (2021)

CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors
por: Azhar, Ambreen, et al.
Publicado: (2022)

87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up
por: Woolley, Ann E, et al.
Publicado: (2019)

Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series
por: Franco, Antonio, et al.
Publicado: (2023)

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
por: Chen, Ruoyang, et al.
Publicado: (2021)

Transplant of a Kidney from a Hepatitis C Viremic Donor to a Naïve Recipient without Viral Transmission: A Case Report
por: Rawashdeh, Badi, et al.
Publicado: (2021)

Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients
por: Duerr, Michael, et al.
Publicado: (2020)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Heart Transplant Using Hepatitis C-Seropositive and Viremic Organs in Seronegative Recipients
por: Zhu, Yuanjia, et al.
Publicado: (2020)

Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome
por: Nowak, Knut Michael, et al.
Publicado: (2016)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
por: Zhang, Jian, et al.
Publicado: (2019)

Trends and three-year outcomes of hepatitis C virus–viremic donor heart transplant for hepatitis C virus–seronegative recipients
por: Ruck, Jessica M., et al.
Publicado: (2022)

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients
por: Ferri, Flaminia, et al.
Publicado: (2019)

The use of HCV positive donors among non-HCV infected liver transplant recipients
por: Zaffar, Duha, et al.
Publicado: (2022)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
por: Cotter, Thomas G., et al.
Publicado: (2021)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
por: Gambato, Martina, et al.
Publicado: (2023)

Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
por: Zhang, Hedong, et al.
Publicado: (2022)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Longer-Term Clinical Outcomes From the THINKER and EXPANDER Trials of Transplantation of HCV-RNA+ Donor Kidneys Into Hepatitis C Virus-Negative Recipients
por: Potluri, Vishnu, et al.
Publicado: (2023)

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection
por: Marticorena Garcia, Stephan R., et al.
Publicado: (2021)

Successful use of a hepatitis C viremic donor in pediatric bilateral lobar lung transplantation
por: Kawashima, Mitsuaki, et al.
Publicado: (2022)

Post-transplant outcomes in recipients of living donor kidneys and intended recipients of living donor kidneys
por: Dharia, Atit A., et al.
Publicado: (2022)

JC viraemia in kidney transplant recipients: to act or not to act?
por: Rao, N., et al.
Publicado: (2012)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
por: Shen, Chao, et al.
Publicado: (2020)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Adult Living-Donor Kidney Transplantation, Donor Age, and Donor–Recipient Age
por: Hiramitsu, Takahisa, et al.
Publicado: (2021)

Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys
por: Steinbrink, Julie M., et al.
Publicado: (2023)

The Psychosocial Burden of HCV Infection and the Impact of Antiviral Therapy on the Quality of Life in Liver and Kidney Transplant Recipients: A Pilot Study
por: Santonicola, Antonella, et al.
Publicado: (2020)

Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report
por: Cuvelier, Susan, et al.
Publicado: (2021)

Living Donor Kidney Transplant in Recipients With Glomerulonephritis: Donor Recipient Biologic Relationship and Allograft Outcomes
por: El-Rifai, Rasha, et al.
Publicado: (2023)

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients
por: Pietrosi, Giada, et al.
Publicado: (2020)

Donor's Versus Recipient's Demographic Data for Estimating Kidney Function in Kidney Transplant Recipients
por: Nabiee, Morteza, et al.
Publicado: (2019)

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors
por: Wiesmann, F., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h3omqm0rvfmd1v2ccin9rjj8sv